Sushant A. Patil

Sushant A. Patil

Auto-generated profile, based on publicly available information

Sushant A. Patil

Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 January 2018 in Blood Advances
Verified
Journal Article
Closed access
PDF file
MDMichael W. Drazer
Michael W. Drazer
SKSabah Kadri
Sabah Kadri
MSMadina Sukhanova
Madina Sukhanova
SPSushant A. Patil
Sushant A. Patil
AWAllison H. West
Allison H. West
LGLucy A. Godley
Lucy A. Godley
Next-generation sequencing (NGS)–based targeted gene capture panels are used to profile hematopoietic malignancies to guide prognostication and treatment decisions. Because these panels include genes associated with hereditary hematopoietic malignancies (HHMs), we hypothesized that these panels could identify pathogenic germ line variants in malignant cells, thereby identifying patients at risk for HHMs. In total, pathogenic or likely pathogenic variants in ANKRD26, CEBPA, DDX41, ETV6, GATA2, RUNX1, or TP53 were identified in 74 (21%) of 360 patients. Germ line tissue was available for 24 patients with 25 pathogenic or likely pathogenic variants with variant allele frequencies >0.4. Six (24%) of these 25 variants were of germ line origin. Three DDX41 variants, 2 GATA2 variants, and a TP53 variant previously implicated in Li-Fraumeni syndrome were of germ line origin. No likely pathogenic/pathogenic germ line variants possessed variant allele frequencies <0.4. This study demonstrates that NGS-based prognostic panels may identify individuals at risk for HHMs despite not being designed for this purpose. Furthermore, variants known to cause Li-Fraumeni syndrome as well as known pathogenic variants in genes such as DDX41 and GATA2 are especially likely to be of germ line origin. Thus, tumor-based panels may augment, but should not replace, comprehensive germ line–based testing and counseling. Key Points NGS-based prognostic panels may identify individuals at risk for HHMs despite not being designed for this purpose. Variant allele frequency >0.4 and gene of interest may be predictive of germ line origin. Visual Abstract

1 July 2018 in American Journal of Surgical Pathology
Verified
Journal Article
Closed access
PDF file
MPMegan Parilla
Megan Parilla
SKSabah Kadri
Sabah Kadri
SPSushant A. Patil
Sushant A. Patil
LRLauren Ritterhouse
Lauren Ritterhouse
JSJeremy Segal
Jeremy Segal
TATatjana Antic
Tatjana Antic
Eosinophilic solid and cystic renal cell carcinomas (ESC RCC) is a rare, unique tumor type not yet included in the World Health Organization classification of renal neoplasia. Separately, RCCs found in patients with tuberous sclerosis complex (TSC) have recently been categorized into 3 morphologic groups: RCC with a tubulopapillary architecture separated by smooth muscle stroma, chromophobe-like, and eosinophilic-microcytic type. The third classification has been identified in ∼11% of TSC-associated RCC and have histology identical to ESC RCCs. The sporadic form of ESC RCC, not associated with TSC, have only been characterized on the cytogenetic level and the full molecular underpinnings have yet to be examined. Using next-generation sequencing we present 2 cases of sporadic ESC RCC in patients without clinical features of tuberous sclerosis, which demonstrate pathogenic somatic TSC2 gene mutations. These mutations are without other alterations in any other genes associated with RCC, suggesting that sporadic ESC RCC may be characterized by somatic tuberous sclerosis gene mutations (TSC2).

1 August 2019 in American Journal of Surgical Pathology
Verified
Journal Article
Closed access
MPMegan Parilla
Megan Parilla
MAMir Alikhan
Mir Alikhan
MAMustafa Al-Kawaaz
Mustafa Al-Kawaaz
SPSushant Patil
Sushant Patil
SKSabah Kadri
Sabah Kadri
TATatjana Antic
Tatjana Antic
Renal cell carcinoma (RCC) with leiomyomatous stroma is a provisional category of RCC in the 2016 World Health Organization Classification of Tumors of the Urinary System. Microscopic examination of hematoxylin and eosin–stained sections reveals this entity to be well-circumscribed with tubulopapillary growth of cells with clear cytoplasm in a background of leiomyomatous stroma. Herein we describe the genetic features of 15 University of Chicago Medical Center archived cases with hematoxylin and eosin histology matching the provisional diagnosis. Immunohistochemical (IHC) stains revealed 1/15 of these tumors to be clear cell renal cell carcinoma (ccRCC) and 6/15 to be clear cell papillary renal cell carcinoma (ccpRCC), demonstrating the morphologic overlap with these discrete known entities. Interestingly 3/6 of the ccpRCCs had chromosome 18 gain suggesting there may be novel specific genetic changes in ccpRCC with leiomyomatous stroma. Of the remaining 8 tumors with IHC staining patterns that do not fit either ccRCC or ccpRCC only 3 of these had mutations in the recently described TCEB1 gene with concurrent monosomy of chromosome 8. These 3 cases had a somewhat unique IHC pattern that possibly could separate them from the 5 other non-ccRCC/non-ccpRCC cases. This descriptive study, although small, demonstrates the difficulty in applying the current World Health Organization provisional criteria at a single institution with suggestion of an immunohistochemcial panel that may assist in the diagnosis of TCEB1-mutated RCC with leiomyomatous stroma.

1 October 2019 in Laboratory Investigation
Verified
Journal Article
Closed access
PDF file
DCDavid B. Chapel
David B. Chapel
SPSushant A. Patil
Sushant A. Patil
APAndrei Plagov
Andrei Plagov
RPRutika Puranik
Rutika Puranik
AMAnastasiya Mendybaeva
Anastasiya Mendybaeva
LRLauren L. Ritterhouse
Lauren L. Ritterhouse

28 January 2019 in Journal of Neuropathology & Experimental Neurology
Verified
Journal Article
Closed access
PDF file
MPMegan Parilla
Megan Parilla
SKSabah Kadri
Sabah Kadri
SPSushant A Patil
Sushant A Patil
CFCarrie Fitzpatrick
Carrie Fitzpatrick
LRLauren Ritterhouse
Lauren Ritterhouse
PPPeter Pytel
Peter Pytel
The 2016 WHO classification of brain tumors represents a major step towards the integration of molecular data into pathologic diagnoses. Our institution has included massively parallel sequencing technology in the diagnostic work-up of all gliomas since January 2016. The utilized platform successfully identifies copy number variations, individual gene mutations, small insertions and deletions, and selected gene fusions. Herein, we retrospectively review the first 51 glial tumor samples run for clinical purposes using the UCM-OncoPlus platform, a 1213 gene targeted hybrid-capture next generation sequencing (NGS) panel. NGS paired with histomorphology and clinical data allowed for reliable, comprehensive, and cost-effective classification of all the analyzed gliomas (51/51) with minimal tissue required and without the need for additional testing. In addition to detecting all diagnostically relevant mutations according to the 2016 WHO system, our data suggest a large NGS-based platform may improve the accuracy of classifying gliomas beyond the 2016 WHO system, to provide truly personalized diagnostics. Furthermore, this methodology assists in classifying histologically challenging or clinically unusual cases. And, finally, the versatile nature of this testing methodology allows for near effortless expansion as new therapeutic targets and prognostic markers are discovered.

1 July 2019 in Human Pathology
Verified
Journal Article
Closed access
LALindsay Alpert
Lindsay Alpert
LYLindsay Yassan
Lindsay Yassan
RPRachel Poon
Rachel Poon
SKSabah Kadri
Sabah Kadri
NNNifang Niu
Nifang Niu
NSNamrata Setia
Namrata Setia